SK Bioscience stock reports KRW 156 billion Q2 revenue

SK Bioscience stock stood at KRW 35,750 on the Korea Exchange on September 23, 2026, while the company reported Q2 2026 revenue of KRW 156 billion, down 3.8 percent year over year. The combination puts the latest quarterly loss beside a share price positioned 41.7 percent below its 52-week high of KRW 61,300.

Revenue slips in Q2

According to ATS View on September 18, 2026, SK Bioscience generated KRW 156 billion in Q2 2026 revenue, a 3.8 percent year over year decline. The same report puts the operating loss at KRW 15.7 billion for the quarter.

The comparison with the prior year matters because revenue contracted while the operating line remained negative. For investors, the latest report therefore points to earnings conversion rather than sales volume as the central measure of progress.

Vaccines and CDMO drive strategy

SK Bioscience operates in vaccines and biopharmaceutical manufacturing. The Chosun Daily reported on September 7, 2026, that the company is seeking improved earnings and new growth engines, with the IDT Biologika acquisition identified as an important part of that effort.

The operating result gives that strategy a measurable test. Q2 revenue of KRW 156 billion was accompanied by a KRW 15.7 billion operating loss, a spread that leaves cost absorption and the contribution from acquired operations central to the next earnings comparison.

Stock remains below yearly high

SK Bioscience had a market capitalization of KRW 2,804,821,769,750 on September 23, 2026. Its 52-week range was KRW 31,800 to KRW 61,300, placing the KRW 35,750 quote 12.4 percent above the low and 41.7 percent below the high.

The KRX price was unchanged at 0.00 percent on September 23, 2026. The market snapshot and the Q2 figures together frame SK Bioscience as a vaccine and biopharmaceutical company whose next valuation signal depends on a narrower operating loss and renewed revenue growth.